Insulin Resistance

Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease

Top

Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014. DOI:10.2337/db14-0287.

Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease

Top

De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014. DOI:10.2337/db13-1954.

Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI?

Top

Biessels GJ, Reijmer YD. Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes. 2014. DOI:10.2337/db14-0384.

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults

Top

Neeland IJ, Turer AT, Ayers CR, Powell Wiley TM, Vega GL, Farzaneh Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150-1159. The risk of type 2 diabetes mellitus is heterogeneous among obese individuals. Factors that discriminate prediabetes or diabetes risk within this population have not been well characterized.

Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.

Top

Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695-704. The Swedish Obese Subjects (SOS) study compared the long-term effects of bariatric surgery with the effects of usual care for type 2 diabetes prevention among 3,429 subjects with obesity.

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Top

Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428. The authors of the current prospective study sought to examine the potential benefits of laparoscopic Roux-en-Y gastric bypass (LRYGB) among those with BMI 30-34.9 kg/m2 (class I obesity) and type 2 diabetes.

Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study

Top

Lorenzo C, Lee R, Haffner SM. Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study. Diabetes Care. 2012 Aug 24. Epub ahead of print. The Diabetes Prevention Program (DPP) reported no racial/ethnic differences in the incidence of diabetes in individuals with impaired glucose tolerance (IGT). Therefore, it has been hypothesized that factors associated with racial/ethnic disparities act prior to the development of IGT.

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction

Top

Continuous coverage of ADA 2012. Perreault L, Pan Q, Mather KJ, et al; for the Diabetes Prevention Program Research Group. DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction. Lancet. 2012;379(9833):2243-2251. This report sought to quantify and predict diabetes risk reduction during the long-term follow-up to the Diabetes Prevention Program (DPP), the Diabetes Prevention Program Outcomes Study (DPPOS).

1 2 3 4 5 6 7 8 9 10  ... Next